Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Oct;24(4):285-286.
doi: 10.14744/AnatolJCardiol.2020.91376.

Ambrisentan-induced severe asymptomatic thrombocytopenia

Dana Kigitovica  1 , Matiss Šablinskis  2 , Sandra Lejniece  1 , Aivars Lejnieks  1 , Andris Skride  1
Affiliations
Case Reports

Ambrisentan-induced severe asymptomatic thrombocytopenia

Dana Kigitovica et al. Anatol J Cardiol. 2020 Oct.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Response of platelet count after discontinuation of ambrisentan and therapy with methylprednisolone
See this image and copyright information in PMC

References

    1. Fischer A, Denton CP, Matucci-Cerinic M, Gillies H, Blair C, Tislow J, et al. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial. Respir Med. 2016;117:254–63. - PubMed
    1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. ESC Scientific Document Group 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension:The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):Endorsed by:Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur Heart J. 2016;37:67–119. - PubMed
    1. Buckley MS, Wicks LM, Staib RL, Kirejczyk AK, Varker AS, Gibson JJ, et al. Pharmacokinetic evaluation of ambrisentan. Expert Opin Drug Metab Toxicol. 2011;7:371–80. - PubMed
    1. Wei A, Gu Z, Li J, Liu X, Wu X, Han Y, et al. Clinical Adverse Effects of Endothelin Receptor Antagonists:Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials. J Am Heart Assoc. 2016;5 doi:10.1161/JAHA.116.003896. - PMC - PubMed
    1. A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) (cited 2020 Feb 19) Available from: URL;https://clinicaltrials.gov/ct2/show/NCT00578786 .

Publication types